696 reports of this reaction
4.1% of all VISMODEGIB reports
#9 most reported adverse reaction
DECREASED APPETITE is the #9 most commonly reported adverse reaction for VISMODEGIB, manufactured by Genentech, Inc.. There are 696 FDA adverse event reports linking VISMODEGIB to DECREASED APPETITE. This represents approximately 4.1% of all 17,013 adverse event reports for this drug.
Patients taking VISMODEGIB who experience decreased appetite should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DECREASED APPETITE is moderately reported among VISMODEGIB users, representing a notable but not dominant share of adverse events.
In addition to decreased appetite, the following adverse reactions have been reported for VISMODEGIB:
The following drugs have also been linked to decreased appetite in FDA adverse event reports:
DECREASED APPETITE has been reported as an adverse event in 696 FDA reports for VISMODEGIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DECREASED APPETITE accounts for approximately 4.1% of all adverse event reports for VISMODEGIB, making it a notable side effect.
If you experience decreased appetite while taking VISMODEGIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.